Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines

Timo Vesikari, Jin Xu, David R Johnson, Jessie Hall, Tomáš Marček, Michelle G Goveia, Camilo J Acosta, Andrew Wen-Tseng Lee, Timo Vesikari, Jin Xu, David R Johnson, Jessie Hall, Tomáš Marček, Michelle G Goveia, Camilo J Acosta, Andrew Wen-Tseng Lee

Abstract

In randomized active-comparator controlled studies, DTaP5-HB-IPV-Hib showed comparable immunogenicity and safety to other licensed vaccines. This study assessed persistence of anti-hepatitis B surface antigen (HBs) and anti-pertussis antibodies, when children were 4 to 5 years of age, 3 to 4 years after initial infant/toddler hexavalent vaccination. This was an extension of 2 European studies in which infants/toddlers received either DTaP5-HB-IPV-Hib or DTaP3-HB-IPV/Hib on a 2 + 1 or 3 + 1 schedule. Primary endpoints included percentages with anti-HBs ≥10 mIU/mL, and anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertactin (PRN), and anti-fimbriae types 2 & 3 (FIM) greater than or equal to the lower limit of quantitation (LLOQ). One month after 2 + 1 or 3 + 1 dosing, nearly all toddlers had anti-HBs ≥10 mIU/mL, and responded to the received pertussis antigens. Approximately 3 to 4 years later, 65.8%-70.2% in the DTaP5-HB-IPV-Hib and 82.0%-83.7% in the DTaP3-HB-IPV/Hib groups, respectively, had anti-HBs ≥10 mIU/mL. Percentages of children with pertussis antibodies above LLOQ after 2 + 1 dosing were 58.4% and 41.5% (anti-PT), 80.9% and 88.3% (anti-FHA), 66.1% and 72.6% (anti-PRN), and 94.4% and 3.3% (anti-FIM), in the DTaP5-HB-IPV-Hib and DTaP3-HB-IPV/Hib groups, respectively. This study demonstrated, as expected, waning of hepatitis B and pertussis antibodies during the 3 to 4 years after completion of a 3 + 1 or 2 + 1 hexavalent vaccination schedule. Nonetheless, anti-HBs levels ≥10 IU/mL and detectable antibodies against acellular pertussis antigens persisted in most study participants. The implications of these findings for the long-term prevention of hepatitis B and pertussis are further discussed.

Keywords: Hepatitis B; antibodies; hexavalent; infants; persistence; pertussis; toddlers; vaccine.

References

    1. Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V.. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11:2132–41. doi:10.1080/21645515.2015.1044180.
    1. Wallace AS, Mantel C, Mayers G, Mansoor O, Gindler JS, Hyde TB. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine. 2014;32:5301–10. doi:10.1016/j.vaccine.2014.07.076.
    1. Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017;13:2494–502. doi:10.1080/21645515.2017.1362515.
    1. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496–500. doi:10.1097/INF.0b013e31805d7f17.
    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507–12. doi:10.1097/01.inf.0000222413.47344.23.
    1. Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state medicaid population. Pediatr Infect Dis J. 2009;28:98–101. doi:10.1097/INF.0b013e318187d047.
    1. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506–12.
    1. GlaxoSmithKline Biologicals sa . INFANRIX-hexa summary of product characteristics. Rixensart (Belgium), 2000.
    1. Sanofi Pasteur Europe . HEXYON summary of product characteristics. Marcy l’Etroile (France): European Medicines Agency; 2013.
    1. MCM vaccine B. V. VAXELIS summary of product characteristics. Leiden (The Netherlands): European Medicines Agency; 2019.
    1. Euopean Medicines Agency . Assessment report. Hexyon. 2013.
    1. European Medicines Agency . 2015. Assessment report for paediatric studies submitted according to article 46 of the regulation (EC) No 1901/2006. Infanrix® Hexa.
    1. Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36:209–15. doi:10.1097/INF.0000000000001406.
    1. Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 2016;34:3810–16. doi:10.1016/j.vaccine.2016.05.054.
    1. Collett D. Modelling binary data. London, UK: Chapman & Hall/CRC; 2003.
    1. Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010;17:1055–65. doi:10.1128/CVI.00131-10.
    1. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907–16. doi:10.1016/s0264-410x(98)00227-8.
    1. Kohberger RC, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine. 2008;26:3516–21. doi:10.1016/j.vaccine.2008.04.016.
    1. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008;26:6587–91. doi:10.1016/j.vaccine.2008.09.034.
    1. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, Bell BP. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27:881–85. doi:10.1097/INF.0b013e31817702ba.
    1. Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu S-N, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158–66. doi:10.1016/j.vaccine.2005.03.017.
    1. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958–64. doi:10.1016/j.vaccine.2007.06.059.
    1. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009;27:1858–62. doi:10.1016/j.vaccine.2009.01.027.
    1. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet J-M. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat. 2011;18:369–75. doi:10.1111/j.1365-2893.2010.01312.x.
    1. Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, Mrazek J, Hozakova L, Zjevikova A, Pliskova L. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395–400. doi:10.1007/s15010-010-0039-7.
    1. Su F-H, Cheng S-H, Li C-Y, Chen J-D, Hsiao C-Y, Chien -C-C, Yang Y-C, Hung -H-H, Chu F-Y. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085–90. doi:10.1016/j.vaccine.2007.09.013.
    1. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2:e753. doi:10.1371/journal.pone.0000753.
    1. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey S, Jeffries D, Hall A, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis. 2006;193:1528–35. doi:10.1086/jid.2006.193.issue-11.
    1. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404–09. doi:10.1016/j.jinf.2008.08.008.
    1. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin. Infect. Dis. 2011;53:68–75. doi:10.1093/cid/cir270.
    1. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al. Antibody levels and protection after hepatitis b vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214:16–22. doi:10.1093/infdis/jiv748.
    1. Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball M, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214:273–80. doi:10.1093/infdis/jiw142.
    1. Zanetti AR, Romano L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis. 2010;10:755–61. doi:10.1016/S1473-3099(10)70195-X.
    1. Zanetti A, Parlato A, Romano L, Desole MG, Ferrera G, Giurdanella F, Zuliani M, Richard P, Thomas S, Fiquet A. Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy. Vaccine. 2012;30:5770–75. doi:10.1016/j.vaccine.2012.06.078.
    1. Giambi C, Bella A, Barale A, Montu D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008;8:100. doi:10.1186/1471-2334-8-100.
    1. Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, et al. Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin. 2009;5:592–98. doi:10.4161/hv.9051.
    1. Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine. 2000;18(Suppl 1):S35–8. doi:10.1016/s0264-410x(99)00460-0.
    1. Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis. 2016;214:1–3. doi:10.1093/infdis/jiv750.
    1. Robert Koch-Institut . Statement of the German standing committee on vaccination at the RKI recommendations of the standing committee on vaccination (STIKO) at the robert koch institute – 2017/2018. Epidemiologisches Bull. 24 of August 2017. 2017;34:333–76.
    1. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine. 2008;26:3142–52. doi:10.1016/j.vaccine.2007.11.096.
    1. Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, HogenEsch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine. 2009;27:888–92. doi:10.1016/j.vaccine.2008.11.078.
    1. Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM, Nadig KB, Liska V, Schödel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates. Vaccine. 2012;30:1476–80. doi:10.1016/j.vaccine.2011.12.095.
    1. Gilbert CL, Klopfer SO, Martin JC, Schodel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin. 2011;7:1336–42. doi:10.4161/hv.7.12.18333.
    1. Gilbert CL, Stek JE, Villa G, Klopfer SO, Martin JC, Schodel FP, Bhuyan PK. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients. Vaccine. 2014;32:6521–26. doi:10.1016/j.vaccine.2014.09.015.
    1. Vesikari T, Martin JC, Liss CL, Liska V, Schodel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 2011;30:e109–13. doi:10.1097/INF.0b013e31821ed1a4.
    1. Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin. 2009;5:92–97. doi:10.4161/hv.5.2.6587.
    1. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96:548–57.
    1. Plotkin SA. Complex correlates of protection after vaccination. Clin. Infect. Dis. 2013;56:1458–65. doi:10.1093/cid/cit048.
    1. Queenan AM, Dowling DJ, Cheng WK, Fae K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, et al. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. Vaccine. 2019;37:80–89. doi:10.1016/j.vaccine.2018.11.028.
    1. Gorringe AR, Vaughan TE. Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert Rev Vaccines. 2014;13:1205–14. doi:10.1586/14760584.2014.930667.
    1. European Centre for Disease Prevention and Control . Vaccine schedules in all coutries of the European Union. 2018.
    1. Centers for Disease Control and Prevention . Recommended immunization schedule for children and adolescents aged 18 years or younger, UNITED STATES, 2018. 2018.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner